Last reviewed · How we verify

Intravenous Lidocaine

Khon Kaen University · FDA-approved active Small molecule

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia and infiltration anesthesia, Ventricular arrhythmias (acute management), Chronic pain conditions (off-label use in some settings).

At a glance

Generic nameIntravenous Lidocaine
Also known as2%Intravenous Lidocaine, IV lidocaine, lignocaine, Xylocaine, Chlorydrate de Lidocaine 2%
SponsorKhon Kaen University
Drug classLocal anesthetic; antiarrhythmic agent
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia; Cardiology; Pain management
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and the generation of action potentials, thereby blocking pain signal transmission. When administered intravenously, it can also have systemic effects including antiarrhythmic properties and anti-inflammatory effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: